News
Clovis' Rubraca is latest PARP drug showing promise in pancr...
Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies seek new uses outside ovarian cancer where this class first gained a fo
